MENU
+Compare
HNSBF
Stock ticker: OTC
AS OF
Nov 6 closing price
Price
$2.91
Change
-$1.67 (-36.46%)
Capitalization
372.04M

HNSBF Hansa Medical AB Forecast, Technical & Fundamental Analysis

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer... Show more

HNSBF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for HNSBF with price predictions
Jan 15, 2026

HNSBF sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for HNSBF moved below the 200-day moving average on January 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for HNSBF entered a downward trend on December 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (27.498). P/E Ratio (0.000) is within average values for comparable stocks, (51.030). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.891). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (10.893) is also within normal values, averaging (323.037).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HNSBF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNSBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
HNSBF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Scheelevagen 22
Phone
+46 46165670
Employees
159
Web
https://www.hansabiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMCPX37.220.48
+1.31%
ClearBridge Mid Cap 1
GMAPX31.380.37
+1.19%
Goldman Sachs Small Cap Eq Insghts P
CPTUX88.250.62
+0.71%
Invesco Discovery Large Cap R5
PMVQX28.650.19
+0.67%
PGIM Quant Solutions Mid-Cap Val R6
RBCRX13.080.03
+0.23%
RBC China Equity R6

HNSBF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with ENSC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HNSBF
1D Price
Change %
HNSBF100%
N/A
ENSC - HNSBF
33%
Loosely correlated
-3.23%
MLLCF - HNSBF
27%
Poorly correlated
N/A
GNPX - HNSBF
25%
Poorly correlated
+14.98%
GRI - HNSBF
25%
Poorly correlated
+1.22%
SPRB - HNSBF
24%
Poorly correlated
-4.44%
More